Related Experiment Video
Updated: Aug 7, 2025

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
FAM193A is a positive regulator of p53 activity
Maria M Szwarc1, Anna L Guarnieri1, Molishree Joshi2
1Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Abstract:
Inactivation of the p53 tumor suppressor, either by mutations or through hyperactivation of repressors such as MDM2 and MDM4, is a hallmark of cancer. Although many inhibitors of the p53-MDM2/4 interaction have been developed, such as Nutlin, their therapeutic value is limited by highly heterogeneous cellular responses. We report here a multi-omics investigation of the cellular response to MDM2/4 inhibitors, leading to identification of FAM193A as a widespread regulator of p53 function. CRISPR screening identified FAM193A as necessary for the response to Nutlin. FAM193A expression correlates with Nutlin sensitivity across hundreds of cell lines. Furthermore, genetic codependency data highlight FAM193A as a component of the p53 pathway across diverse tumor types. Mechanistically, FAM193A interacts with MDM4, and FAM193A depletion stabilizes MDM4 and inhibits the p53 transcriptional program. Last, FAM193A expression is associated with better prognosis in multiple malignancies. Altogether, these results identify FAM193A as a positive regulator of p53.
Insights
FAM193A is a newly identified regulator of the p53 pathway, crucial for cancer drug response. Its expression predicts patient outcomes, highlighting its role in tumor suppression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Inactivation of the p53 tumor suppressor is common in cancer.
- MDM2 and MDM4 are key repressors of p53.
- Current p53-MDM2/4 inhibitors show limited therapeutic value due to heterogeneous responses.
Purpose of the Study:
- To investigate the cellular response to MDM2/4 inhibitors.
- To identify novel regulators of the p53 pathway.
- To explore the therapeutic potential of targeting p53 regulation.
Main Methods:
- Multi-omics investigation
- CRISPR screening
- Analysis of genetic codependency data
- Protein interaction studies
Main Results:
- FAM193A was identified as a necessary regulator for response to Nutlin (p53-MDM2/4 inhibitor).
- FAM193A expression correlates with Nutlin sensitivity across numerous cell lines.
- FAM193A interacts with MDM4, and its depletion stabilizes MDM4, inhibiting p53.
- FAM193A expression is linked to better prognosis in several cancers.
Conclusions:
- FAM193A is a positive regulator of p53.
- FAM193A represents a potential therapeutic target for enhancing p53 pathway activity in cancer.
- FAM193A's role in p53 regulation and prognostic significance warrants further investigation.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Positive Regulator Molecules

